Ioakeimidis 2018.

Study characteristics
Methods	Design: Randomized controlled trial Recruitment: Not specified Setting: Hospital, Greece. Study start date/Study end date: Not specified
Participants	Total N: 54 N per arm: Arm 1: 27; Arm 2: 27 Inclusion criteria: ≥10 cpd Motivation to quit Hospitalized with acute coronary syndrome (ACS) 18 or older Exclusion criteria: Prior EC use History of neuropsychiatric disorders Prior varenicline use or use of SC pharmacotherapy at time of ACS Cardiogencic shock or renal impairment Hepatic impairment prior to ACS Excessive alcohol use or current use of marijuana or non‐cigarette tobacco products Inclusion based on specific population characteristic: People who have experienced acute coronary syndrome 65% women; mean age 52; mean cpd 21; mean FTND 5.6 Motivated to quit: Yes E‐cigarette use at baseline: No prior EC use
Interventions	EC: information on whether cig‐a‐like or refillable not provided Both arms given "low intensity counselling" Intervention 1: 12‐week use of EC 12 mg/ml nicotine Intervention 2: 12‐week varenicline
Outcomes	Weeks: 4, 12, 24 Cessation: 7‐day PP at 24 weeks, self‐report Adverse events and biomarkers: Unclear how these were reported. Abstract says no SAEs, poster implies this may have just been CV or neuropsychiatric SAEs. Abstract says nothing about AEs but nausea and sleeping disorders given in table in poster. Implies (S)AEs collected during treatment period only Other outcomes measured: Not specified
Study funding	Not reported
Author declarations	Not reported
Notes	New for 2020 update. Abstract and poster only; limited data available
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not specified
Allocation concealment (selection bias)	Unclear risk	Not specified
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Not specified but equal amounts of contact and support between arms so performance bias judged unlikely
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Self‐report only but equal amounts of contact between arms, no reason to suspect differential misreport
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not specified
Selective reporting (reporting bias)	Unclear risk	Abstract/poster only so not able to judge
Other bias	High risk	Abstract and poster only. Two different figures presented for quit rate in EC arm (no difference in those presented in varenicline arm) between abstract and poster. Poster percentage aligns with figure, so using that (16.5%) as opposed to abstract figure (32.5%). Contacted authors but no reply. Calculated n quit based on percentages but unclear what denominators were; EC calculates back to whole number for EC but not for varenicline